Distribution of circulating cardiac biomarkers in healthy children: from birth through adulthood

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Canadian Paediatric Society. Treatment decisions regarding infants, children and adolescents. Paediatr. Child Health 9(2), 99–103 (2004).
  MedlineGoogle Scholar
• 2 Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 123(5), 551–565 (2011).
  MedlineGoogle Scholar
• 3 Cantinotti M, Law Y, Vittorini S et al. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update. Heart Fail. Rev. 19(6), 727–742 (2014). • The aim of this review was to describe the diagnostic and prognostic relevance of measurement of brain natriuretic peptide (BNP) and N-terminal probrain natriuretic peptide (NT-proBNP) in pediatric patients with heart failure.
  MedlineGoogle Scholar
• 4 Colantonio DA, Kyriakopoulou L, Chan MK et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin. Chem. 58(5), 854–868 (2012). •• The CALIPER study should assist laboratorians and pediatricians in interpreting test results more accurately and thereby lead to improved diagnosis of childhood diseases and reduced patient risk.
  Medline CASGoogle Scholar
• 5 Benjamin Jung, Khosrow Adeli. Clinical laboratory reference intervals in pediatrics: the CALIPER initiative. Clin. Biochem. 42(16–17), 1589–1595 (2009).
  MedlineGoogle Scholar
• 6 Flanders MM, Crist RA, Roberts WL et al. Pediatric reference intervals for seven common coagulation assays. Clin. Chem. 51(9), 1738–1742 (2005).
  Medline CASGoogle Scholar
• 7 Roth-Cline M, Gerson J, Bright P et al. Ethical considerations in conducting pediatric research. Hand. Exp. Pharmacol. 205, 219–244 (2011). •• The critical need for pediatric research on drugs and biological products underscores the responsibility to ensure that children are enrolled in clinical research that is both scientifically necessary and ethically sound.
  MedlineGoogle Scholar
• 8 Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 15, 128(16), 1810–1852 (2013).
  MedlineGoogle Scholar
• 9 Pastormerlo LE, Maffei S, Latta DD et al. N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. Eur. J. Prev. Cardiol. 23(4), 366–376 (2015).
  MedlineGoogle Scholar
• 10 Cantinotti M, Scalese M, Murzi B et al. Echocardiographic nomograms for chamber diameters and areas in Caucasian children. J. Am. Soc. Echocardiogr. 27, 1279–1292 (2014).
  MedlineGoogle Scholar
• 11 Prontera C, Zucchelli CG, Vittorini S et al. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassauys for NT-proBNP. Clin. Chim. Acta 400, 70–73 (2009). • The analytical characteristics of immunoassays for NT-proBNP were evaluated and compared.
  Medline CASGoogle Scholar
• 12 Storti S, Masotti S, Prontera C et al. Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples. Clin. Chim. Acta 451(Pt B), 129–134 (2015). • The analytical characteristics of immunoassays for hs-cTnI were evaluated and compared.
  Medline CASGoogle Scholar
• 13 Krintus M, Kozinski M, Boudry P et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin. Chem. Lab. Med. 52(11), 1657–1665 (2014).
  Medline CASGoogle Scholar
• 14 Mueller T, Dieplinger B. The Presage^® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev. Mol. Diagn. 13(1), 13–30 (2013). • Reports detailed characteristics of ST2 and its plasma evaluation.
  Medline CASGoogle Scholar
• 15 La'ulu SL, Apple FS, Murakami MM et al. Performance characteristics of the ARCHITECT Galectin-3 assay. Clin. Biochem. 46(1–2), 119–122 (2013).
  MedlineGoogle Scholar
• 16 Clerico A, Passino C, Franzini M et al. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin. Chim. Acta 443, 17–24 (2015).
  Medline CASGoogle Scholar
• 17 Passino C, Barison A, Vergaro G et al. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin. Chim. Acta 443, 29–38 (2015).
  Medline CASGoogle Scholar
• 18 Venge P, Johnston N, Lindahl B et al. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J. Am. Coll. Cardiol. 54, 1165–1172 (2009).
  Medline CASGoogle Scholar
• 19 Kavsak PA, Macrae AR, Yerna MJ et al. Analytic and clinical utility of a next generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin. Chem. 55, 573–577 (2009).
  Medline CASGoogle Scholar
• 20 Mingels A, Jacobs L, Michielsen E et al. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin. Chem. 55, 101–108 (2009). •• The hs-cTnT assay was the only assay tested with a performance capability sufficient to detect cTn concentrations in healthy individuals.
  Medline CASGoogle Scholar
• 21 Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial tissue renewal? Clin. Chem. Lab. Med. 47, 1167–1177 (2009).
  Medline CASGoogle Scholar
• 22 Koerbin G, Potter JM, Abhayaratna WP et al. Longitudinal studies of cardiac troponin I in a large cohort of healthy children. Clin. Chem. 58, 1665–1672 (2012). •• Description of the distribution of hs-cTnI in a large cohort of healthy children aged 8, 10 and 12 years.
  Medline CASGoogle Scholar
• 23 Koerbin G, Potter JM, Abhayaratna WP et al. The distribution of cardiac troponin I in a population of healthy children: lessons for adults. Clin. Chim. Acta 417, 54–56 (2013).
  Medline CASGoogle Scholar
• 24 Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 298(5601), 2188–2190 (2002).
  Medline CASGoogle Scholar
• 25 Porrello ER, Mahmoud AI, Simpson E et al. Transient regenerative potential of the neonatal mouse heart. Science 331(6020), 1078–1080 (2011).
  Medline CASGoogle Scholar
• 26 Soonpaa MH, Kim KK, Pajak L et al. Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol. 271(5 Pt 2), H2183–H2189 (1996).
  Medline CASGoogle Scholar
• 27 Laflamme MA, Murry CE. Heart regeneration. Nature 473(7347), 326–335 (2011).
  Medline CASGoogle Scholar
• 28 Vela D, Buja LM. Quest for the cardiovascular holy grail: mammalian myocardial regeneration. Cardiovasc. Pathol. 17(1), 1–5 (2008).
  MedlineGoogle Scholar
• 29 Mollova M, Bersell K, Walsh S et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc. Natl Acad. Sci. USA 110(4), 1446–1451 (2013).
  Medline CASGoogle Scholar
• 30 Daniels LB, Maisel AS. Cardiomyocyte proliferation contributes to developmental heart growth in young humans, suggesting that children and adolescents may be able to regenerate myocardium. Cardiovascular biomarkers and sex: the case for women. Nat. Rev. Cardiol. 12(10), 588–596 (2015).
  Medline CASGoogle Scholar
• 31 Nir A, Lindinger A, Rauh M et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr. Cardiol. 30(1), 3–8 (2009).
  MedlineGoogle Scholar
• 32 Albers S, Mir TS, Haddad M et al. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin. Chem. Lab. Med. 44(1), 80–85 (2006).
  Medline CASGoogle Scholar
• 33 Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin. Chem. 49(9), 1563–1564 (2003).
  Medline CASGoogle Scholar
• 34 Schwachtgen L, Herrmann M, Georg T et al. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol. 94(6), 399–404 (2005).
  Medline CASGoogle Scholar
• 35 Nir A, Bar-Oz B, Perles Z et al. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr. 93(5), 603–607 (2004).
  Medline CASGoogle Scholar
• 36 Cantinotti M, Storti S, Parri MS et al. Reference intervals for brain natriuretic peptide in healthy newborns and infants measured with automated immunoassay platform. Clin. Chem. Lab. Med. 48, 697–700 (2010).
  Medline CASGoogle Scholar
• 37 Mir TS, Laux R, Hellwege HH et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 112, 896–899 (2003).
  MedlineGoogle Scholar
• 38 Clerico A, Fontana M, Vittorini S et al. The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: Proposal for a working hypothesis. Clin. Chim. Acta 405, 1–7 (2009).
  Medline CASGoogle Scholar
• 39 Clerico A, Passino C, Emdin M. When gonads talk to the heart sex hormones and cardiac endocrine function. J. Am. Coll. Cardiol. 58, 627–628 (2011).
  Medline CASGoogle Scholar
• 40 Clerico A, Giannoni A, Vittorini S et al. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am. J. Physiol. Heart Circ. Physiol. 301, H12–H20 (2011).
  Medline CASGoogle Scholar
• 41 Meeusen JW, Johnson JN, Gray A et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin. Biochem. 48(18), 1337–1340 (2015).
  Medline CASGoogle Scholar
• 42 Christenson RH, Duh SH, Wu AH et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin. Biochem. 43(7–8), 683–690 (2010).
  Medline CASGoogle Scholar